HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • September 23, 2026

Share

  • 1

    HHS announced an RFI on September 23, 2026, regarding access to deceased donor islet cells for type 1 diabetes treatment.

  • 2

    The RFI seeks public feedback on whether current FDA regulations hinder access to deceased donor islet cell therapies.

  • 3

    HHS is considering if unmodified deceased donor islet cells should be classified as organs for transplantation.

  • 4

    The proposed change could transfer oversight from the FDA to HRSA and the Organ Procurement and Transplantation Network.

  • 5

    HHS encourages public comments on the RFI by November 8, 2026, to gather information on improving patient access.

Original Source(s)

HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments

  • by Assistant Secretary for Public Affairs (ASPA)

  • September 23, 2026

Related Content

Incidence and baseline predictors of discontinuation in DRCRnet studies

Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance

Ovulation may shift preferences toward conspicuous luxury

Across 3 studies, higher fertility was associated with greater preference for luxury when it was visible, personally relevant, and potentially noticeable to others.